Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

14. Juli 2025 03:01 ET | Quelle: Truveta

New study reveals shift in pediatric obesity treatment following AAP guidelines

BELLEVUE, Wash., July 14, 2025 (GLOBE NEWSWIRE) -- A groundbreaking study published today in Pediatrics Open Science shows a notable increase in the use of medication to treat pediatric obesity in...
14. Februar 2025 17:51 ET | Quelle: Robbins LLP

NVO STOCK NEWS: NVO Shareholders with Large Losses Should Contact Robbins LLP for Information About the Class Action Lawsuit Against Novo Nordisk A/S

Robbins LLP is Investigating Allegations that Novo Nordisk A/S (NVO) Misled Investors Regarding REDEFINE-1, Novo’s Phase 3 CagriSema Study on Obesity
31. Januar 2025 11:18 ET | Quelle: Truveta

New Truveta study highlights patterns of discontinuation and reinitiation of GLP-1 RA medications

BELLEVUE, Wash., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Truveta’s groundbreaking study analyzing real-world use of GLP-1 receptor agonist (GLP-1 RA) therapies in adults with overweight or obesity has...
08. Januar 2025 18:46 ET | Quelle: Robbins LLP

Stockholder Notice: Robbins LLP Informs Stockholders of the BioAge Labs, Inc. Class Action

Robbins LLP is Investigating Allegations that BioAge Labs, Inc. (BIOA) Misled Investors Regarding its Lead Drug Candidate in Connection with its IPO
27. November 2023 09:00 ET | Quelle: Truveta

Largest real-world study finds tirzepatide (Mounjaro) up to three times more effective than semaglutide (Ozempic) for weight loss

BELLEVUE, Wash., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Today Truveta announced new comparative effectiveness research exploring weight loss among patients taking semaglutide (Ozempic) and tirzepatide...